申请日期 | 2025-07-13 | 申请号 | KR1020117012364 |
公开(公告)号 | KR1020110096536A | 公开(公告)日 | 2011-08-30 |
公开国别 | KR | 申请人省市代码 | 全国 |
申请人 | ABBOTT BIOTHERAPEUTICS CORP; CLEVELAND CLINIC FOUNDATION | ||
简介 | Uses of anti-CS1 antibodies, alone or in combination with other agents, for the treatment of rare lymphomas, such as NK lymphomas, NK/T-cell lymphomas, and angioimmunoblastic lymphomas. |
您还没有登录,请登录后查看下载地址
|